1. Executive Summary 2. Renal Cell Carcinoma (RCC) - Disease Overview 2.1 Etiology and Pathophysiology 2.1.1 Etiology 2.1.2 Pathophysiology 2.2 Renal Cell Carcinoma Staging 2.3 Symptoms 2.4 Prognosis 2.5 Potential Biomarkers 2.5.1 Molecular Markers in Serum 2.5.2 Molecular Markers in Urine 3. Renal Cell Carcinoma (RCC) - Epidemiology 3.1 Disease Background 3.2 Risk Factors and Comorbidities 3.3 Incidence 4. Global Renal Cell Carcinoma - Epidemiological Forecast (2012 - 2023) 4.1 Renal Cell Carcinoma - Global Diagnosed Incident Cases (Ages ≥20 Years) and Forecast 4.2 Renal Cell Carcinoma - Global Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast 5. Global Renal Cell Carcinoma (RCC) - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (2012 - 2023) 5.1 United States RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) 5.1.1 RCC - United States Diagnosed Incident Cases (Ages ≥20 Years) and Forecast 5.1.2 RCC - United States Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast 5.2 Italy RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) 5.2.1 RCC - Italy Diagnosed Incident Cases (Ages ≥20 Years) and Forecast 5.2.2 RCC - Italy Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast 5.3 Germany RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) 5.3.1 RCC - Germany Diagnosed Incident Cases (Ages ≥20 Years) and Forecast 5.3.2 RCC - Germany Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast 5.4 France RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) 5.4.1 RCC - France Diagnosed Incident Cases (Ages ≥20 Years) and Forecast 5.4.2 RCC - France Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast 5.5 United Kingdom RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) 5.5.1 RCC - United Kingdom Diagnosed Incident Cases (Ages ≥20 Years) and Forecast 5.5.2 RCC - United Kingdom Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast 5.6 Spain RCC- Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) 5.6.1 RCC - Spain Diagnosed Incident Cases (Ages ≥20 Years) and Forecast 5.6.2 RCC - Spain Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast 5.7 Japan RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) 5.7.1 RCC - Japan Diagnosed Incident Cases (Ages ≥20 Years) and Forecast 5.7.2 RCC - Japan Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast 5.8 China RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) 5.8.1 RCC - China Diagnosed Incident Cases (Ages ≥20 Years) and Forecast 5.8.2 RCC - China Five-Year Diagnosed Prevalent Cases (Ages ≥20 Years) and Forecast 6. Global Renal Cell Carcinoma - Drugs Market Analysis (2012 - 2021) 6.1 Global Renal Cell Carcinoma - Drugs Market and Forecast 6.2 Global Renal Cell Carcinoma - Drugs Market Share and Forecast 7. Global Renal Cell Carcinoma - Major Branded Drugs Product Profiles and Sales 7.1 Sutent (Sunitinib) - Product Profile and Sales 7.1.1 Sutent (Sunitinib) - Product Profile 7.1.2 Sutent (Sunitinib) - Global Sales and Forecast (2012 - 2021) 7.2 Nexavar (Sorafenib) - Product Profile and Sales 7.2.1 Nexavar (Sorafenib) - Product Profile 7.2.2 Nexavar (Sorafenib) - Global Sales and Forecast (2012 - 2021) 7.3 Votrient (Pazopanib) - Product Profile and Sales 7.3.1 Votrient (Pazopanib) - Product Profile 7.3.2 Votrient (Pazopanib) - Global Sales and Forecast (2012 - 2021) 7.4 Avastin (Bevacizumab) - Product Profile and Sales 7.4.1 Avastin (Bevacizumab) - Product Profile 7.4.2 Avastin (Bevacizumab) - Global Sales and Forecast (2012 - 2021) 7.5 Afinitor (Everolimus) - Product Profile and Sales 7.5.1 Afinitor (Everolimus) - Product Profile 7.5.2 Afinitor (Everolimus) - Global Sales and Forecast (2012 - 2021) 7.6 Inlyta (Axitinib) - Product Profile and Sales 7.6.1 Inlyta (Axitinib) - Product Profile 7.6.2 Inlyta (Axitinib) - Global Sales and Forecast (2012 - 2021) 7.7 Torisel (Temsirolimus) - Product Profile and Sales 7.7.1 Torisel (Temsirolimus) - Product Profile 7.7.2 Torisel (Temsirolimus) - Global Sales and Forecast (2012 - 2021) 7.8 Proleukin (Aldesleukin) - Product Profile and Sales 7.8.1 Proleukin (Aldesleukin) - Product Profile 7.8.2 Proleukin (Aldesleukin) - Global Sales and Forecast (2012 - 2021) 7.9 Opdivo (Nivolumab) - Product Profile 7.10 Tarceva (Erlotinib) - Product Profile 7.11 Interferon-alfa - Product Profile 8. Global Renal Cell Carcinoma Drugs Market - Company Wise Pipeline Analysis 8.1 Merck & Co., Inc. 8.2 Merck & Co., Inc. 8.3 Exelixis Inc 8.4 Argus Therapeutics, Inc. 8.5 Bristol-Myers Squibb 8.6 Genentech/Roche 8.7 Immatics Biotechnologies 8.8 AVEO Oncology 8.9 Eisai 8.10 Acceleron 8.11 Rexahn Pharmaceuticals 8.12 Bionomics 8.13 Cerulean Pharma Inc. 8.14 Celldex Therapeutics 8.15 TVAX Biomedical 8.16 TRACON Pharmaceuticals 8.17 Eli Lilly 8.18 AstraZeneca 9. Global Renal Cell Carcinoma Drugs - Market Drivers 9.1 Rising Incidence of Renal Cell Carcinoma Expected to Fuel Market Growth 9.2 Increasing Elderly Population Likely to Drive Renal Cell Carcinoma Drugs Market 9.3 Strong Pipeline Candidates is Expected to Drive Market Growth 9.4 Novel Treatment Option for Renal Cell Carcinoma 10. Global Renal Cell Carcinoma Drugs - Market Restraints 10.1 High Prices of Branded Renal Cell Carcinoma Drugs 10.2 Increasing Preference for Generic Drug Variants Would Hamper the Market

List of Figures: Figure 4-1: Global - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 4-2: Global - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 4-3: Global - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 4-4: Global - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-1: United States - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-2: United States - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-3: United States - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-4: United States - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-5: Italy - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-6: Italy - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-7: Italy - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-8: Italy - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-9: Germany - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-10: Germany - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-11: Germany - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-12: Germany - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-13: France - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-14: France - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-15: France - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-16: France - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-17: United Kingdom - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-18: United Kingdom - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-19: United Kingdom - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-20: United Kingdom - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-21: Spain - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-22: Spain - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-23: Spain - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-24: Spain - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-25: Japan - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-26: Japan - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-27: Japan - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-28: Japan - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-29: China - Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-30: China - Forecast for Diagnosed Incident Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 5-31: China - Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2012 - 2015 Figure 5-32: China - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥20 Years (Number), 2016 - 2023 Figure 6-1: Global - Renal Cell Carcinoma Drugs Market (Million US$), 2012 - 2015 Figure 6-2: Global - Forecast for Renal Cell Carcinoma Drugs Market (Million US$), 2016 - 2021 Figure 6-3: Global - Renal Cell Carcinoma Drugs Market Share (Percent), 2012 - 2015 Figure 6-4: Global - Forecast for Renal Cell Carcinoma Drugs Market Share (Percent), 2016 - 2021 Figure 7-1: Sutent (Sunitinib) - Global Sales (Million US$), 2012 - 2015 Figure 7-2: Sutent (Sunitinib) - Forecast for Global Sales (Million US$), 2016 - 20121 Figure 7-3: Nexavar (Sorafenib) - Global Sales (Million US$), 2012 - 2015 Figure 7-4: Nexavar (Sorafenib) - Forecast for Global Sales (Million US$), 2016 - 2021 Figure 7-5: Votrient (Pazopanib) - Global Sales (Million US$), 2012 - 2015 Figure 7-6: Votrient (Pazopanib) - Forecast for Global Sales (Million US$), 2016 - 2021 Figure 7-7: Avastin (Bevacizumab) - Global Sales (Million US$), 2012 - 2015 Figure 7-8: Avastin (Bevacizumab) - Forecast for Global Sales (Million US$), 2016 - 2021 Figure 7-9: Afinitor (Everolimus) - Global Sales (Million US$), 2012 - 2015 Figure 7-10: Afinitor (Everolimus) - Forecast for Global Sales (Million US$), 2016 - 2021 Figure 7-11: Inlyta (Axitinib) - Global Sales (Million US$), 2012 - 2015 Figure 7-12: Inlyta (Axitinib) - Forecast for Global Sales (Million US$), 2016 - 2021 Figure 7-13: Torisel (Temsirolimus) - Global Sales (Million US$), 2012 - 2015 Figure 7-14: Torisel (Temsirolimus) - Forecast for Global Sales (Million US$), 2016 - 2021 Figure 7-15: Proleukin (Aldesleukin) - Global Sales (Million US$), 2012 - 2015 Figure 7-16: Proleukin (Aldesleukin) - Forecast for Global Sales (Million US$), 2016 - 2021 Figure 9-1: World Population - Over 60 Years of Age (Thousand), 2012 - 2015 Figure 9-2: World Population - Forecast for Over 60 Years of Age (Thousand), 2016 - 2021 List of Tables: Table 2-1: Percentage of People Surviving the Cancer (Percent) Table 2-2: Potential Serum Biomarkers in Renal Cell Carcinoma Table 2-3: Potential Urinary Biomarkers in Renal Cell Carcinoma Table 9-1: Renal Cell Carcinoma - List of Drugs in the Pipeline (February 2016)

GlaxoSmithKline, Sanofi Pasteur, Merck, Novartis, Pfizer, Roche, Exelixis Inc, Argus Therapeutics, Inc, Bristol-Myers Squibb, Genentech, Immatics Biotechnologies, AVEO Oncology, Eisai , Acceleron , Rexahn Pharmaceuticals, Bionomics, Cerulean Pharma Inc , Celldex Therapeutics, TVAX Biomedica, TRACON Pharmaceuticals, Eli Lilly, AstraZeneca,